Shanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals

Simply Wall St.06-21

Shanghai Henlius Biotech (SEHK:2696) has just cleared two regulatory hurdles that matter for investors, with GMP approval for HANBEIYOU production in China and a new gastric cancer indication for its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645099773?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-21 03:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645099773","market":"hk","top_or_hot":-1,"title":"Shanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals","media":"Simply Wall St.","content":"<div>\n<p>Shanghai Henlius Biotech (SEHK:2696) has just cleared two regulatory hurdles that matter for investors, with GMP approval for HANBEIYOU production in China and a new gastric cancer indication for its ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-stock-could-be-worth-a-loo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-21 03:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-stock-could-be-worth-a-loo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Henlius Biotech (SEHK:2696) has just cleared two regulatory hurdles that matter for investors, with GMP approval for HANBEIYOU production in China and a new gastric cancer indication for its ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-stock-could-be-worth-a-loo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-stock-could-be-worth-a-loo","article_id":"2645099773","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-stock-could-be-worth-a-loo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645099773","pubTimestamp":1781983901,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Shanghai Henlius Biotech (SEHK:2696) has just cleared two regulatory hurdles that matter for investors, with GMP approval for HANBEIYOU production in China and a new gastric cancer indication for its HANSIZHUANG immunotherapy.\nSee our latest analysis for Shanghai Henlius Biotech.\nThese regulatory approvals arrive after a mixed stretch for Shanghai Henlius Biotech’s stock, with the share price up 7.51% year to date but down 11.45% over the past month. The 1-year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","XBI":"SPDR S&P Biotech ETF","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","02696":"复宏汉霖","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK4588":"碎股","BK1161":"生物科技","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4585":"ETF&股票定投概念","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4581":"高盛持仓"},"translate_title":"中国肿瘤学批准后，上海复宏汉霖生物科技（SEHK：2696）股票可能值得关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02696":0.9,"XBI":1.5},"content_text":"Shanghai Henlius Biotech (SEHK:2696) has just cleared two regulatory hurdles that matter for investors, with GMP approval for HANBEIYOU production in China and a new gastric cancer indication for its HANSIZHUANG immunotherapy. See our latest analysis for Shanghai Henlius Biotech. These regulatory approvals arrive after a mixed stretch for Shanghai Henlius Biotech’s stock, with the share price up 7.51% year to date but down 11.45% over the past month. The 1-year total shareholder return of 31.25% and very large 3-year total shareholder return, close to 5x, suggest longer term momentum has been strong. If you are tracking how new oncology and immunotherapy products can reshape portfolios, it is a good time to scan for other healthcare and biotech opportunities through 131 healthcare AI stocks With Shanghai Henlius Biotech reporting revenue of CN¥6,666.6m, net income of CN¥827.0m and the stock trading at HK$63.00 with a sizeable discount to some valuation estimates, is this a genuine opportunity or is the market already pricing in future growth? AdvertisementPreferred P/E of 35.8x: Is It Justified For Shanghai Henlius Biotech? Shanghai Henlius Biotech is trading on a P/E of 35.8x, which is paired with a HK$63.00 share price and a sizeable discount to some fair value estimates based on cash flow. That multiple sits against a backdrop of analysts seeing earnings growing, but at rates that are not flagged as especially high compared to some other opportunities in the Hong Kong market. The P/E ratio compares the current share price with the company’s earnings per share, so a higher P/E usually reflects investors paying more today for each unit of current earnings. For a biotech group like Shanghai Henlius Biotech, focused on oncology and autoimmune therapies, a premium P/E can also reflect expectations around the commercial potential of its biologic pipeline and recently approved products. In this case, the stock is described as expensive versus both the estimated fair P/E of 17.3x and the Asian biotech industry average of 29.2x, as well as the peer average of 26.5x. That is a wide gap, which suggests the market is currently assigning a materially higher earnings multiple than these comparative benchmarks, and the level could shift if sentiment or earnings expectations change over time. Explore the SWS fair ratio for Shanghai Henlius Biotech Result: Price-to-Earnings of 35.8x (OVERVALUED). However, Shanghai Henlius Biotech still faces risks if product uptake underwhelms or regulatory timelines shift, which could challenge the earnings expectations that support a premium P/E. Find out about the key risks to this Shanghai Henlius Biotech narrative. Another View: SWS DCF Model Points To A Different Story While the P/E of 35.8x makes Shanghai Henlius Biotech look expensive relative to its fair ratio of 17.3x and to industry averages, the SWS DCF model points the other way. With an estimated future cash flow value of HK$173.75 versus a HK$63.00 share price, the stock screens as materially undervalued. How much weight do you place on earnings multiples compared with cash flow models when they disagree this sharply? Look into how the SWS DCF model arrives at its fair value. 2696 Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 212 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Given the mix of signals around Shanghai Henlius Biotech, it helps to look past headlines, act promptly, and test the data against your own thesis using the 4 key rewards and 1 important warning sign Looking for more investment ideas beyond Shanghai Henlius Biotech? If you like what Shanghai Henlius Biotech brings to your watchlist, it makes sense to widen the search and line up a few more high conviction ideas.  Target higher quality opportunities by scanning 212 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their financial profile. Strengthen your income stream by reviewing 497 dividend fortresses that focus on companies offering substantial yields supported by their current financials. Build resilience into your portfolio by shortlisting 285 resilient stocks with low risk scores that show lower overall risk scores compared with many typical market options.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645099773","isCrawlerRequest":true}